Mehnert, Janice M.

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 969

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 642

Atg7 Overcomes Senescence and Promotes Growth of Braf V600E-Driven Melanoma

Xie, X., Koh, J. Y., Price, S., White, E., & Mehnert, J. M. (2015) · Cancer Discovery

Autophagy in Disease and TherapyMelanoma and MAPK Pathways

Cited by 208

Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma

Xie, X., White, E. P., & Mehnert, J. M. (2013) · PLoS ONE

Autophagy in Disease and TherapyPI3K/AKT/mTOR signaling in cancer

Cited by 150

Biomarkers for Response to Immune Checkpoint Blockade

Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 51